Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders for ImmuCell Corporation, held remotely on June 11, 2026. The meeting addressed corporate governance, executive compensation, equity plans, and charter amendments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the results of shareholder votes and does not contain financial performance data.
Material Changes and Voting Results
With 7,397,695 shares present (over 81% of eligible votes), shareholders approved all five proposals:
- Director Elections: All seven nominees were elected to one-year terms. Broker non-votes totaled 2,209,901 shares for each nominee.
- Executive Compensation: The non-binding advisory resolution passed with 92.4% of votes cast in favor.
- 2025 Stock Option and Incentive Plan: Approved with 90.39% of votes cast in favor.
- Charter Amendment: An amendment to the Certificate of Incorporation regarding officer exculpation under Delaware law was approved with 53.62% of total shares outstanding voting in favor.
- Auditor Ratification: Wipfli LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 99.28% of votes cast in favor.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural outcomes of the annual meeting.
Investor Verification Checklist
- Verify the specific terms of the newly approved 2025 Stock Option and Incentive Plan.
- Review the exact language of the Certificate of Incorporation amendment regarding officer exculpation.
- Confirm the composition of the newly elected Board of Directors.
- Check subsequent filings for the company's audited financial results for the fiscal year ending December 31, 2025.